Back to search

Article

The Impact of Comorbidities, Neutrophil-to-lymphocyte Ratio, and Adverse Events on Quality of Life in Lung Cancer Patients Receiving EGFR-TKI Therapy

2022-09-28

Abstract excerpt

<h4>Background: </h4> Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are used as the standard first-line treatment for patients with advanced EGFR -mutated non-small cell lung cancer (NSCLC). However, the impact of clinical factors, including comorbidities and treatment-related adverse events (AEs), on quality of life (QoL) was seldom investigated. Objective We aimed to investigate the as...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
129588f1-7099-5ba2-a5b0-c0753e88f005
DOI
10.21203/rs.3.rs-2067050/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Impact of Comorbidities, Neutrophil-to-lymphocyte Ratio, and Adverse Events on Quality of Life in Lung Cancer Patients Receiving EGFR-TKI TherapyDOI 10.21203/rs.3.rs-2067050/v1
Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors.Semantic proximity
A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients.Semantic proximity
Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.Semantic proximity
Quality of Life and Symptoms of Hospitalized Hematological Cancer PatientsSemantic proximity
Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK.Semantic proximity
Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients.Semantic proximity
Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma.Semantic proximity
Analysis of Influence Factors of Quality of Life of Lung Cancer Patients with Skin Adverse Drug Reactions Under Targeted TherapySemantic proximity
Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.Semantic proximity
The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity
Target-Adverse Events and Fear of Cancer Progression, Anxiety, and Depression in Patients with Advanced Non-Small Cell Lung CancerSemantic proximity
Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptor-mutant non-small cell lung cancer: A prospective, multicenter, dose-modification study.Semantic proximity
Select a neighboring publication to make it the new centre.